• Procurement and T-cell production eligibility: a previously evaluation confirmed autologous peripheral blood mononuclear cells can be used for T-cell production

• Written informed consent and authorization for release of personal health information

• Subject has adequate performance status as defined by ECOG score of ≤ 2.

• Expected life expectancy is no less than 12 weeks.

• Subjects must have histologically or cytologically confirmed ovarian cancer. And cancer tissue or ascitic cancer cells are measured positive for B7H3 expression.

• Subjects must have recurrent or refractory disease after or during first-line treatment.

• Defined as:

• Radiographic progression or Continuous Elevation of CA125.

• Subjects must have evaluable disease - defined as:

• Measurable disease with tumor length ≥ 10mm or enlarged lymph nodes ≥ 15mm according to RECIST v1.1 criteria.

• Adequate organ function - defined as:

∙ Blood routine:

∙ white blood cell count ≥ 3 × 10\^9 / L; neutrophil count ≥ 1.5 × 10\^9 / L; hemoglobin ≥ 9g/dL; platelet count ≥ 80 × 10\^9 / L; INR\< 1.5 × ULN; PT, APTT\< 1.5 × ULN

‣ The liver, kidney, lung and cardiopulmonary function:

• Urea and serum creatinine ≤ 1.5 × ULN; Left ventricular ejection fraction ≥ 40%; Baseline oxygen saturation ≥ 95%; Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN.

• Not pregnant with negative serum pregnancy test within 3 days prior to enrollment.

⁃ Female subjects of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of highly effective methods of contraception from the time of informed consent until 8 weeks after study treatment discontinuation.

⁃ \-